Kaya Selcuk
Karadeniz Technical University, School of Medicine, Department of Infectious Diseases and Clinical Microbiology, 61080, Trabzon, Turkey.
Recent Pat Inflamm Allergy Drug Discov. 2012 May;6(2):159-64. doi: 10.2174/187221312800166822.
Sepsis continues to be a very important cause of morbidity and mortality despite advances in modern medicine. It is the cause of mortality in approximately 28-50% of the patients, with the risk increasing particularly in patients with multiple organ dysfunctions. Although anti-infective treatment and securing hemostasis form the cornerstone in the management of this condition, studies to develop new drugs are expected to reduce mortality in severely septic patients. Recombinant human activated protein C (rhAPC) was known as an anti-inflammatory agent with proven efficacy in severe sepsis patients and had a critical effect in the reduction of mortality when administered in the right dose and duration so far, but unfortunately current studies indicate that it was unable to show favorable effects of rhAPC on patients with severe sepsis. For this reason, interests are becoming focused on some other new approaches such as antioxidant treatments, stem cells, computer-implemented sepsis alerting systems, endotoxin removal devices. These attempts may reduce the incidence of mortality due to sepsis in the near future. Some patents on sepsis have also been reviewed in this article.
尽管现代医学取得了进展，但脓毒症仍然是发病和死亡的一个非常重要的原因。它是约28%至50%患者的死亡原因，尤其是在多器官功能障碍患者中风险增加。虽然抗感染治疗和确保止血是这种疾病管理的基石，但开发新药的研究有望降低严重脓毒症患者的死亡率。重组人活化蛋白C（rhAPC）曾被认为是一种抗炎药物，在严重脓毒症患者中具有已证实的疗效，并且到目前为止，在以正确的剂量和持续时间给药时对降低死亡率有关键作用，但不幸的是，目前的研究表明它对严重脓毒症患者无法显示出有利影响。因此，人们的兴趣正集中在一些其他新方法上，如抗氧化治疗、干细胞、计算机实施的脓毒症警报系统、内毒素清除装置。这些尝试可能在不久的将来降低脓毒症导致的死亡率。本文还对一些脓毒症相关专利进行了综述。
